Lung Cancer

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Amishi Desai, MD, assistant professor of medicine at Upstate University Hospital, discusses the use of immunotherapy in patients with non–small cell lung cancer (NSCLC) with PD-L1 expression less than 1%.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses biomarkers for immune response in non–small cell lung cancer.

Some immune-related adverse events associated with immune checkpoint inhibitor therapies may prove to be higher than the data reported in the trials that led to the drugs’ initial FDA approval.

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Manju P. Paul, MD, assistant professor of medicine at Upstate University Hospital, discusses the pulmonologist’s role as part of the multidisciplinary approach in treating patients with non–small cell lung cancer (NSCLC).

Manju P. Paul, MD, discusses new diagnostic and staging techniques that are advancing standards of care in patients with lung cancer.

Juergen Wolf, MD, medical director, Center for Integrated Oncology, University Hospital of Cologne, Köln Bonn, Köln, Germany, discusses the GEOMETRY study in patients with MET-positive non–small cell lung cancer (NSCLC).

Stephen L. Graziano, MD, discusses available and emerging targeted therapies for common driver mutations in patients with non–small cell lung cancer and the sequencing strategies beyond frontline treatment.

Adham Jurdi, MD, discusses how the updated data from the PACIFIC trial have changed the standard of care for patients with stage III non–small cell lung cancer.

Recent data have moved the needle across the board in oncology, specifically with lung cancer and gastrointestinal cancers, with immunotherapy and targeted agents paving the way for an improvement in survival outcomes.

Over the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, compares liquid and tissue biopsies for the treatment of patients with advanced non–small cell lung cancer.

Nisha A. Mohindra, MD, discusses the current treatment landscape, challenges faced in this patient population, and what she believes will be a focus for further research over the next decade.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses the FDA approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

The FDA has approved atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.

The phase III TAHOE trial evaluating second-line rovalpituzumab tesirine as a treatment for patients with advanced small cell lung cancer has stopped enrollment as recommended by an Independent Data Monitoring Committee.

Robert J. Cerfolio, MD, MBA, director, Lung Cancer Center, chief, clinical thoracic surgery, discusses the impact of minimally invasive surgery in the management of non–small cell lung cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the role of immunotherapy in the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

Stephen Liu, MD, discusses ongoing developments in the treatment of patients with ALK-positive NSCLC.

Julie R. Brahmer, MD, discusses updates on the use of immunotherapy in patients with metastatic non–small cell lung cancer.

Within the last decade, 4 tyrosine kinase inhibitors have been approved for the frontline treatment of patients with EGFR-positive non–small cell lung cancer.

Tumor mutational burden has been shown in studies to predict response to immunotherapies in certain types of cancer and is being validated in clinical trials as a biomarker of response.

Pembrolizumab has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer, but thoracic oncologists need to be aware of potentially severe immune-related adverse events.

Ardaman Shergill, MD, discusses the impact of tumor mutational burden, as well as RET and NTRK fusions, in the NSCLC paradigm.

Deepa S. Subramaniam, MBBS, MSc, discusses the complex and evolving treatment paradigm of BRAF- and ROS1-driven non–small cell lung cancer.

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to targeted therapies in oncogene-driven non–small cell lung cancer.

The European Commission has approved brigatinib (Alunbrig) for the treatment of adult patients with ALK-positive non–small cell lung cancer who were previously treated with crizotinib (Xalkori).

Mary Jo Fidler, MD, discusses the latest developments in the treatment of patients with ALK-positive lung cancer.